PMID- 36740965
OWN - NLM
STAT- MEDLINE
DCOM- 20230310
LR  - 20230315
IS  - 2093-5978 (Electronic)
IS  - 2093-596X (Print)
IS  - 2093-596X (Linking)
VI  - 38
IP  - 1
DP  - 2023 Feb
TI  - Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond.
PG  - 25-33
LID - 10.3803/EnM.2022.1642 [doi]
AB  - The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), 
      for people with type 2 diabetes and/or obesity, are now firmly established. The 
      evidence-base arising from head-to-head comparative effectiveness studies in 
      people with type 2 diabetes, as well as the recommendations by professional 
      guidelines suggest that GLP1 receptor agonists should replace more traditional 
      treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) 
      inhibitors. Furthermore, their benefits in reducing cardiovascular events in 
      people with type 2 diabetes beyond improvements in glycaemic control has led to 
      numerous clinical trials seeking to translate this benefit beyond type 2 
      diabetes. Following early trial results their therapeutic benefit is currently 
      being tested in other conditions including fatty liver disease, kidney disease, 
      and Alzheimer's disease.
FAU - Viljoen, Adie
AU  - Viljoen A
AD  - Borthwick Diabetes Research Centre, Lister Hospital (East and North Hertfordshire 
      NHS Trust), Stevenage, UK.
FAU - Bain, Stephen C
AU  - Bain SC
AD  - Department of Biomedical Sciences, Swansea University Medical School, Swansea, 
      UK.
LA  - eng
PT  - Journal Article
DEP - 20230206
PL  - Korea (South)
TA  - Endocrinol Metab (Seoul)
JT  - Endocrinology and metabolism (Seoul, Korea)
JID - 101554139
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - Hypoglycemic Agents/therapeutic use/pharmacology
MH  - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use/pharmacology
MH  - *Kidney Diseases
PMC - PMC10008669
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Glucagon-like peptide 1
OT  - Renal insufficiency, chronic
COIS- CONFLICTS OF INTEREST Adie Viljoen has received lecture honoraria and/or, 
      advisory board honoraria and/or, travel support and/or, conducts research trials 
      (for which he receives no remuneration) funded by Amarin, Amgen, Astra Zeneca, 
      Boehringer Ingelheim, Lilly, Napp, Novartis, Novo Nordisk, Regeneron, Sanofi, 
      Takeda, and Tosoh. Stephen C. Bain has received research support from Healthcare 
      and Research Wales (Welsh Government) and honoraria from Boehringer Ingelheim, 
      Lilly, Merck, Napp, Novo Nordisk, and Sanofi. He has ownership in Glycosmedia 
      (Online diabetes news service).
EDAT- 2023/02/07 06:00
MHDA- 2023/03/11 06:00
PMCR- 2023/02/01
CRDT- 2023/02/06 03:03
PHST- 2022/12/14 00:00 [received]
PHST- 2022/12/28 00:00 [accepted]
PHST- 2023/02/07 06:00 [pubmed]
PHST- 2023/03/11 06:00 [medline]
PHST- 2023/02/06 03:03 [entrez]
PHST- 2023/02/01 00:00 [pmc-release]
AID - EnM.2022.1642 [pii]
AID - enm-2022-1642 [pii]
AID - 10.3803/EnM.2022.1642 [doi]
PST - ppublish
SO  - Endocrinol Metab (Seoul). 2023 Feb;38(1):25-33. doi: 10.3803/EnM.2022.1642. Epub 
      2023 Feb 6.